FRANKLIN LAKES, N.J. (Oct. 1, 2024) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Connor Bates has been named worldwide president of the BD Medication Management Solutions business unit, effective October 1.

In this role, Bates will be responsible for driving the global strategic, operational, quality and commercial excellence of the Medication Management Solutions business unit. He will be based out of San Diego and report to Mike Garrison, executive vice president and president of the BD Medical Segment.

Bates joined BD in 1995 and has made significant contributions through successive roles in marketing, strategic planning, supply chain management, product development, process engineering and manufacturing operations. Since 2019, he has served as vice president and general manager for the worldwide Infusion Solutions business within the Medication Management Solutions business unit. Earlier in his career, Bates held leadership positions within BD Biosciences in the life science research tools and clinical diagnostics businesses.

“Connor is a proven leader who brings a strong track record of results and decades of broad cross-functional experience across the enterprise, including deep knowledge of the Medication Management Solutions business and our infusion platforms,” said Garrison. “This unique insight and expertise will be invaluable as we remain laser-focused on the relaunch of the BD Alaris™ Infusion System and accelerate growth across all of our connected medication management platforms throughout the care continuum.”

Bates holds a B.S. in Mechanical Engineering from Kettering University and an MBA from Harvard Business School.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:
Media:                                                                                                                  Investors:
Troy Kirkpatrick                                                                                                  Adam Reiffe
VP, Public Relations                                                                                           Sr. Director, Investor Relations
858.617.2361                                                                                                    201.847.6927        
troy.kirkpatrick@bd.com                                                                                 adam.reiffe@bd.com